SPECIAL NOTICE

We are working on upgrading our websites and despite our best endeavours have experienced census type calamities for almost a week now. Our apologies, we hope to have all problems resolved by Monday August 15th.

SEARCH BY NAME

BROWSE

Browse Australian listed companies

0-9A B C D E F G H I J K L M N O P Q R S T U V W XY Z

Browse current Australian managed funds

0-9A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

SEARCH BY CODE

Find any Australian or New Zealand company or fund (dead or alive) by using SEARCH above or go directly to the site:

TBG DIAGNOSTICS LIMITED (TDL)

Suspended from ASX

SHARE PRICES

(updated at weekends)

Former (or subsequent) names

Shareholder links

Our website ranking of TDL: rating 5
(5 out of 5)
COMPANY WEBSITE:

 

REGISTRY:

Computershare Investor Services, Level 11 172 St Georges Terrace Perth WA 6000

Tel : +61 (0)3 9415 4000 or 1300 850 505 (within Australia)
Fax : +61 7 3229 9860
RegistryWebsite RegistryEmail

Company details

ISIN: AU000000TDL4
Address: Level 18, 101 Collins Street Melbourne VIC 3000 Australia
Tel:  07 3088 7926 Fax:  07 3394 4394

Date first listed: 22/12/1995
Company Secretary: Justyn Stedwel
Sector: Pharmaceuticals & Biotechnology Industry Group: XHJ
Activities: Research & development of potential biopharmaceutical therapeutics for the treatement of human diseases; development, manufacture, importation & distribution of a range of molecular biology products, consumables & fine chemicals for the scientific researc
OFX Transferring Money Internationally to Free

The company's wholly owned subsisiary, TBG Biotechnology Corp., entered into a distribution agreement with Medigen Biotechnology Corp. on 15 February 2020 to distribute TBG Taiwan's SARS-CoV-2 related diagnostic products, including Rapid Test Kit and Nucleic Acid Test Kit. The Distribution Agreement has expanded Medigen's existing exclusive distribution right granted under the distribution contract previously entered into between TBG Taiwan and Medigen in January 2015 to include the Test Kits. This provides an ability for expansion of the business of manufacturing and distributing the Test Kits through the distribution expertise and network of Medigen.

21/09/2020

The company's wholly owned subsidiary, TBG Biotechnology Corp., has received an Emergency Use Authorisation from the U.S. FDA for its TBG SARS-CoV-2 IgG / IgM Rapid Test Kit.

02/09/2020

The company lodges its Half Yearly Report and Accounts.

31/08/2020

The company lodges its Quarterly Activities Report.

31/07/2020

The company lodges its Appendix 4C - quarterly.

31/07/2020

The company releases the Results of its Meeting.

31/07/2020

TBG Diagnostics Limited's wholly owned subsidiary, TBG Biotechnology Corp., has received an emergency use authorisation from the Taiwan Ministry of Health and Welfare for its ExProbe SARS-CoV-2 Testing Kit.

29/07/2020

The company's 2019 AGM will be held at 12:30 pm (AEST) 31 July 2020 at Boardroom, Level 27 101 Collins Street Melbourne VIC.

26/06/2020

The company releases an Appendix 4G.

15/06/2020

The company lodges its Annual Report to shareholders.

15/06/2020

The company lodges its Full Year Statutory Accounts.

12/06/2020

TBG Biotechnology Corp. has received an Emergency Use Authorisation from the United States Food and Drug Administration for its ExProbe SARS-CoV-2 Testing Kit.

12/06/2020

The company will hold its AGM on 31 July 2020. The time and other details relating to the meeting will be advised in the Notice of Meeting to be sent in due course. The period for nomination of Directors will close on 18 June 2020.

11/06/2020

The company's wholly owned subsidiary, TBG Biotechnology Corp., has received the CE Mark approval for its ExProbe SARS-CoV-2 Testing Kit and SARS-CoV-2 IgG / IgM Rapid Test Kit.

21/05/2020

The company has received notification from TBG Biotechnology Xiamen Inc. that the Chinese Department of Commerce has lifted the bans restricting the exportation of TBG Xiamen's CE Marked COVID-19 Nucleic Acid Test Kits. Following the lift of the export ban the COVID-19 Nucleic Acid Test Kits are now able to be exported from China for sale throughout the European Economic Area subject to individual countries accepting import of the test kit. The company has a 46.65% interest in the equity of TBG Xiamen.

05/05/2020

The company issues a Response to ASX Query Letter.

15/04/2020

TBG Xiamen's COVID-19 Virus Diagnostic Kits do not currently have China medical device product registration certification required under the new export requirements as recently announced by the Chinese Government, therefore TBG Xiamen are currently unable to sell and export their COVID-19 Nucleic Acid Diagnostics Kits from China. Without the China medical device product registration certification, TBG Xiamen is also currently unable to sell their COVID19 Nucleic Acid Diagnostics Kits within China. While TBG Xiamen has received interest from several buyers, in light of these new restrictions no COVID-19 Nucleic Acid Diagnostics Kits will be exported or sold while these restrictions remain in place or until TBG Xiamen receives the required certifications for sale and export.

06/04/2020

The securities of TBG Diagnostics Limited will be suspended from quotation immediately under Listing Rule 17.3, pending further enquires by ASX. The securities will remain suspended until further notice.

19/03/2020

The securities of TBG Diagnostics Limited (the "Company") will be reinstated to official quotation from the commencement of trading on Wednesday, 3 February 2016, following the Company's compliance with listing rule 11.1.3 and Chapters 1 and 2 of the ASX Listing Rules. Security Code: TDL

02/02/2016

name changed from Progen Pharmaceuticals Limited

02/02/2016

ASX Announcements (courtesy of ASX)

 

Your comments

Please read our Terms before viewing comments.

 

Company Updates

Post your comments here

Please read our Terms before posting comments.
OMISSIONS
    You can post a comment here about this company

    Please click in the "I'm not a robot" box and enter the word/figures you see in the image that then appears.

    loading Posting your comments. Please wait...


    Directors' on-market share transactions (last 5)

    rss feeds

    Purchases Sales

    DATEDIRECTORNUMBERPRICEAMOUNT
    11/01/2016Stanley Chang500,000$0.210$105,000
    14/05/2014Jitto Arulampalam40,000$1.010$40,398
    12/03/2014Heng Tang10,000$0.520$5,200
    12/12/2013Heng Tang10,000$0.220$2,196
    06/12/2013Heng Tang33,000$0.227$7,475

    Click here for the last 20 transactions all companies

    Directors & Executives (current)

    NAMETITLEDATE OF APPT
    Jitto ArulampalamExecutive Chairman12/06/2013
    Willy HsuCOO01/02/2019
    Emily LeeNon Exec Director07/12/2015
    Stanley ChangNon Exec Director07/12/2015

    Date of first appointment, title may have changed.

    Directors & Executives (former)

    NAMETITLEDATE OF APPOINTMENTDATE OF RESIGNATION
    Eugene ChengNon Exec Director07/12/201528/05/2019
    Edward ChangNon Exec Director03/02/201628/05/2018
    Christopher HarveyIndependent Director16/03/201507/12/2015
    Hongjen ChangNon Exec Director29/11/201307/12/2015
    Heng TangManaging Director, CEO17/07/200916/03/2015
    Stuart JamesNon Exec Chairman01/07/200928/11/2013
    Woei-Jia JiangDirector16/06/201112/07/2013
    Paul DixonCFO03/04/200912/10/2012
    Thomas BurtNon Exec Director17/07/200930/11/2011
    Sue MacLemanCEO06/04/201026/08/2011

    Date of first appointment, title may have changed.